Jacques Gonella is Director at ANTARES PHARMA, INC. (ATRS). They have made 16 open-market trades across 1 company since 2016, most recently 2019-02-26.
CIK 0001189296
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $72K since 2016, against 15 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATRS | SELL | 2019-02-26 | 2019-02-28 | $3.65 | $730K | -0.3% | -18.7% | -22.5% |
| ATRS | SELL | 2018-10-02 | 2018-10-04 | $3.79 | $1.5M | -5.6% | -6.7% | -24.1% |
| ATRS | SELL | 2018-08-13 | 2018-08-15 | $3.09 | $306K | +12.1% | +0.0% | +3.4% |
| ATRS | SELL | 2018-08-08 | 2018-08-10 | $3.09 | $1.5M | +25.7% | +15.8% | +23.6% |
| ATRS | SELL | 2018-06-15 | 2018-06-20 | $2.95 | $2K | -7.8% | -1.8% | +18.7% |
| ATRS | SELL | 2018-06-11 | 2018-06-13 | $2.73 | $546K | -9.9% | -8.2% | +11.9% |
| ATRS | SELL | 2018-06-05 | 2018-06-07 | $2.70 | $234K | +6.7% | -0.7% | +29.7% |
| ATRS | SELL | 2018-06-01 | 2018-06-05 | $2.62 | $1.1M | +7.8% | +2.2% | +30.6% |
| ATRS | SELL | 2018-05-30 | 2018-06-01 | $2.57 | $920K | +9.8% | -1.5% | +33.6% |
| ATRS | SELL | 2018-05-22 | 2018-05-24 | $2.52 | $743K | +10.8% | +5.6% | +46.8% |
| ATRS | SELL | 2018-05-18 | 2018-05-22 | $2.60 | $110K | +3.2% | +7.6% | +38.8% |
| ATRS | SELL | 2018-05-16 | 2018-05-18 | $2.54 | $762K | +3.6% | +13.1% | +31.0% |
| ATRS | SELL | 2018-05-14 | 2018-05-16 | $2.50 | $500K | -3.1% | +13.3% | +27.5% |
| ATRS | SELL | 2018-05-10 | 2018-05-14 | $2.43 | $730K | +0.4% | +16.9% | +28.5% |
| ATRS | SELL | 2018-05-09 | 2018-05-11 | $2.47 | $1.1M | +1.2% | +11.2% | +18.4% |
| ATRS | BUY | 2016-03-18 | 2016-03-21 | $0.72 | $72K | +10.9% | +8.3% | +25.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.